According to the results published in the Journal of Menopausal Medicine, participants experienced: A 33% reduction in anxiety symptoms A 32% reduction in depressive symptoms Significant improvement in emotional wellbeing without any major side effects Read the study summary here
Several RCTs including SAVORTIMI 53 (saxagliptin) [52], EXAMINE (alogliptin) [53], and TECOS (sitagliptin) [54] have shown that DPP4 inhibitors did not significantly reduce stroke risk [1]
For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission
Camkurt MA, Lavagnino L, Zhang XY, Teixeira AL
Retatrutide is a triple-action agonist that targets three receptors (GIP, GLP-1, and Glucagon), while GLP-1 targets only GLP-1 and GLP-2 targets GLP-1 and GIP
Different compound classes show varying susceptibility to diminished effectiveness over time